Sarah Cannon

Running trials

• Recruiting

  A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  NCT07109726· Phase 1/2· Source

• Recruiting

  A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

  NCT06615050· Phase 3· Source

• Active, not recruiting

  A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

  NCT05608044· Phase 2· Source

• Recruiting

  A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

  NCT05384626· Phase 1/2· Source

• Recruiting

  A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

  NCT04678648· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Gastric and esophageal cancer1 recruiting
• Glioblastoma1 recruiting
• Head and neck cancer1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

  NCT05126433· Phase 2· Source

• Terminated

  A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

  NCT05169489· Phase 1· Source

• Completed

  Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer

  NCT05078775· Source

• Terminated

  Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

  NCT04579757· Phase 1/2· Source

• Completed

  Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents

  NCT03242915· Phase 2· Source

• Completed

  A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

  NCT02614066· Phase 1/2· Source

Trial sites

• Sarah Cannon7 trials
• Sarah Cannon Nashville1 trial
• Sarah Cannon, SCRI Oncology Partners1 trial
• Sarah Cannon, Tennesse Oncology1 trial
• Tennessee Oncology Nashville (Sarah Cannon)1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Metastatic breast cancer33 works · 0 trials